Raptiva suspension extends to Canada
This article was originally published in Scrip
Executive Summary
The suspension of Genentech/Merck KGaA's psoriasis treatment Raptiva (efalizumab) has continued to spread, with Health Canada announcing it too has suspended marketing of the product due to safety concerns.